10.1021/acs.jpcb.2c04346
10.1021/acs.jpcb.2c04346 · doi-reference
AlphaFold, allosteric, and orthosteric drug discovery: ways forward
10.1016/j.drudis.2023.103551 · doi-reference
10.3390/ijms21030847
10.3390/ijms21030847 · doi-reference
10.1126/science.abj8754
10.1126/science.abj8754 · doi-reference
10.1038/s41586-021-03819-2
10.1038/s41586-021-03819-2 · doi-reference
10.1158/2159-8290.cd-18-0903
10.1158/2159-8290.cd-18-0903 · doi-reference
10.1016/s1470-2045(19)30863-0
10.1016/s1470-2045(19)30863-0 · doi-reference
10.1056/nejmoa1413513
10.1056/nejmoa1413513 · doi-reference
10.1016/j.tips.2020.02.001
10.1016/j.tips.2020.02.001 · doi-reference
Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment
10.2147/cmar.s162784 · doi-reference
10.1177/2040620718777467
10.1177/2040620718777467 · doi-reference
Rilpivirine long-acting for the prevention and treatment of HIV infection
10.1097/coh.0000000000000474 · doi-reference
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability
10.7448/ias.16.1.18567 · doi-reference
10.1016/j.pharmthera.2015.10.002
10.1016/j.pharmthera.2015.10.002 · doi-reference
Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction
10.1080/09537104.2018.1514107 · doi-reference
2022 FDA approvals
10.1038/d41573-023-00001-3 · doi-reference
Allosteric modulators of dopamine D2 receptors for fine-tuning of dopaminergic neurotransmission in cns diseases: overview, pharmacology, structural aspects and synthesis
10.3390/molecules28010178 · doi-reference
Chemical and biophysical approaches to allosteric modulation
10.1002/ejoc.202100506 · doi-reference
10.1111/bph.16104
10.1111/bph.16104 · doi-reference
10.1038/s41467-017-00716-z
10.1038/s41467-017-00716-z · doi-reference
10.1021/acschemneuro.7b00185
10.1021/acschemneuro.7b00185 · doi-reference
The effect of allosteric modulators on the kinetics of agonist-G protein-coupled receptor interactions in single living cells
10.1124/mol.110.064493 · doi-reference
10.1016/j.bcp.2018.07.014
10.1016/j.bcp.2018.07.014 · doi-reference
Kinetic analysis of gluconate phosphorylation by human gluconokinase using isothermal titration calorimetry
10.1016/j.febslet.2015.10.024 · doi-reference
Brain dysfunction in phenylketonuria: Is phenylalanine toxicity the only possible cause
10.1007/s10545-008-0946-2 · doi-reference
Phenylalanine reduces synaptic density in mixed cortical cultures from mice
10.1203/01.pdr.0000203091.45988.8d · doi-reference
Calorimetric demonstration of the potential of molecular crowding to emulate the effect of an allosteric activator on pyruvate kinase kinetics
10.1021/bi020064h · doi-reference
Ganaxolone for management of seizures associated with CDKL5 deficiency disorder
10.1016/j.tips.2022.11.007 · doi-reference
Enzyme kinetics by isothermal titration calorimetry: allostery, inhibition, and dynamics
10.3389/fmolb.2020.583826 · doi-reference
10.1021/acs.jpcb.6b01911
10.1021/acs.jpcb.6b01911 · doi-reference
10.1021/jacs.3c04045
10.1021/jacs.3c04045 · doi-reference
10.1021/acs.analchem.1c00055
10.1021/acs.analchem.1c00055 · doi-reference
The pocketome of G-protein-coupled receptors reveals previously untargeted allosteric sites
10.1038/s41467-022-29609-6 · doi-reference
10.1021/ci800324m
10.1021/ci800324m · doi-reference
10.1016/j.bbapap.2016.08.012
10.1016/j.bbapap.2016.08.012 · doi-reference
Poly(ADP-ribosyl)ation as a new posttranslational modification of YB-1
10.1016/j.biochi.2015.10.008 · doi-reference
10.1038/s41586-020-2013-6
10.1038/s41586-020-2013-6 · doi-reference
10.1038/s41467-021-27043-8
10.1038/s41467-021-27043-8 · doi-reference
10.1038/s42003-021-02780-0
10.1038/s42003-021-02780-0 · doi-reference
10.1016/j.molcel.2016.03.008
10.1016/j.molcel.2016.03.008 · doi-reference
